UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae

Antimicrobial Agents and Chemotherapy, 2011-06, Vol.55 (6), p.3002-3004

2011

Volltextzugriff (PDF)

Clinical Pharmacodynamics of Cefepime in Patients Infected with Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy, 2010-03, Vol.54 (3), p.1111-1116

2010

Volltextzugriff (PDF)

In Vivo Efficacy of Simulated Human Dosing Regimens of Prolonged-Infusion Doripenem against Carbapenemase- Producing Klebsiella pneumoniae

Antimicrobial Agents and Chemotherapy, 2010-10, Vol.54 (10), p.4112-4115

2010

Volltextzugriff (PDF)

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model

Antimicrobial Agents and Chemotherapy, 2013-06, Vol.57 (6), p.2809-2814

2013

Volltextzugriff (PDF)

Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane

Antimicrobial Agents and Chemotherapy, 2013-12, Vol.57 (12), p.5924-5930

2013

Volltextzugriff (PDF)

In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms

Antimicrobial Agents and Chemotherapy, 2012-01, Vol.56 (1), p.544-549

2012

Volltextzugriff (PDF)

Comparison of Meropenem MICs and Susceptibilities for Carbapenemase-Producing Klebsiella pneumoniae Isolates by Various Testing Methods

Journal of Clinical Microbiology, 2010-07, Vol.48 (7), p.2402-2406

2010

Volltextzugriff (PDF)

In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug Resistance

Antimicrobial Agents and Chemotherapy, 2010-01, Vol.54 (1), p.557-559

2010

Volltextzugriff (PDF)

Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States

Clinical therapeutics, 2010-04, Vol.32 (4), p.766-779

2010

Volltextzugriff (PDF)

Tissue Penetration and Pharmacokinetics of Tigecycline in Diabetic Patients with Chronic Wound Infections Described by Using In Vivo Microdialysis

Antimicrobial Agents and Chemotherapy, 2010-12, Vol.54 (12), p.5209-5213

2010

Volltextzugriff (PDF)

Comparison of the Activity of a Human Simulated, High-Dose, Prolonged Infusion of Meropenem against Klebsiella pneumoniae Producing the KPC Carbapenemase versus That against Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model

Antimicrobial Agents and Chemotherapy, 2010-02, Vol.54 (2), p.804-810

2010

Volltextzugriff (PDF)

In Vivo Efficacy of 1- and 2-Gram Human Simulated Prolonged Infusions of Doripenem against Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy, 2009-10, Vol.53 (10), p.4352-4356

2009

Volltextzugriff (PDF)

Population Pharmacokinetics of Oseltamivir: Pediatrics through Geriatrics

Antimicrobial Agents and Chemotherapy, 2013-08, Vol.57 (8), p.3470-3477

2013

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae

Antimicrobial agents and chemotherapy, 2023-04, Vol.67 (4), p.e0221321-e0221321

2023

Volltextzugriff (PDF)

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

Clinical cancer research, 2024-05, Vol.30 (10), p.2011-2016

2024

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models

Antimicrobial agents and chemotherapy, 2017-02, Vol.61 (2)

2017

Volltextzugriff (PDF)

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model

Antimicrobial agents and chemotherapy, 2016-04, Vol.60 (4), p.2075-2080

2016

Volltextzugriff (PDF)

Pharmacokinetics–pharmacodynamics, computer decision support technologies, and antimicrobial stewardship: the compass and rudder

Diagnostic microbiology and infectious disease, 2018-08, Vol.91 (4), p.371-382

2018

Volltextzugriff (PDF)

Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies

Antimicrobial agents and chemotherapy, 2014-09, Vol.58 (9), p.5005-5015

2014

Volltextzugriff (PDF)

Reply to “Double-Carbapenem Therapy Not Proven To Be More Active than Carbapenem Monotherapy against KPC-Positive Klebsiella pneumoniae”

Antimicrobial agents and chemotherapy, 2012-07, Vol.56 (7), p.4038-4038

2012

Volltextzugriff (PDF)

PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside

Journal of pharmacokinetics and pharmacodynamics, 2017-04, Vol.44 (2), p.161-177

2017

Volltextzugriff (PDF)

Correction to: PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside

Journal of pharmacokinetics and pharmacodynamics, 2018-04, Vol.45 (2), p.351-351

2018

Volltextzugriff (PDF)

Evaluation of the pharmacokinetics–pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection

Diagnostic microbiology and infectious disease, 2011-05, Vol.70 (1), p.101-111

2011

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae

Clinical Pharmacodynamics of Cefepime in Patients Infected with Pseudomonas aeruginosa

In Vivo Efficacy of Simulated Human Dosing Regimens of Prolonged-Infusion Doripenem against Carbapenemase- Producing Klebsiella pneumoniae

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model

Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane

In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms

Comparison of Meropenem MICs and Susceptibilities for Carbapenemase-Producing Klebsiella pneumoniae Isolates by Various Testing Methods

In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug Resistance

Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States

Tissue Penetration and Pharmacokinetics of Tigecycline in Diabetic Patients with Chronic Wound Infections Described by Using In Vivo Microdialysis

Comparison of the Activity of a Human Simulated, High-Dose, Prolonged Infusion of Meropenem against Klebsiella pneumoniae Producing the KPC Carbapenemase versus That against Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model

In Vivo Efficacy of 1- and 2-Gram Human Simulated Prolonged Infusions of Doripenem against Pseudomonas aeruginosa

Population Pharmacokinetics of Oseltamivir: Pediatrics through Geriatrics

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model

Pharmacokinetics–pharmacodynamics, computer decision support technologies, and antimicrobial stewardship: the compass and rudder

Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies

Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia

Reply to “Double-Carbapenem Therapy Not Proven To Be More Active than Carbapenem Monotherapy against KPC-Positive Klebsiella pneumoniae”

PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside

Erratum for Drusano et al., "Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia"

Correction to: PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside

Evaluation of the pharmacokinetics–pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection

Suchergebnisse filtern